title: Double high-dose chemotherapy followed by autologous peripheral blood stem cell transplantation for primary disseminated medulloblastoma: a report of 3 cases.
abstract: We performed double high-dose chemotherapy followed by peripheral blood stem cell transplantation (PBSCT) in 3 children with medulloblastoma and primary leptomeningial dissemination, including spinal metastasis. After resection of the main tumor mass, 30.6 Gy whole craniospinal radiation therapy and 4 or 5 courses of conventional chemotherapy with vincristine (1.5 mg/m), carboplatin (560 mg/m), ifosfamide (9000 mg/m), and etoposide (500 mg/m), and 2 courses of high-dose thiotepa (680 mg/m) and melphalan (240 mg/m) therapy with PBSCT were administered. Two patients with low erythroblastic leukemia viral oncogene homolog 2 (ERBB2) gene expression achieved long-term survival (41 mo and 40 mo) but the patient with high ERBB2 expression relapsed 9 months after the second PBSCT.
authors.affiliation: Departments of Neurosurgery, Tokyo Women's Medical University Medical Center East, Tokyo, Japan.
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Aihara
authors.forename: Toshihisa
authors.initials: T
authors.lastname: Tsuruta
authors.forename: Takakazu
authors.initials: T
authors.lastname: Kawamata
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Kanno
authors.forename: Katsuya
authors.initials: K
authors.lastname: Maebayashi
authors.forename: Masako
authors.initials: M
authors.lastname: Sakauchi
authors.forename: Emiko
authors.initials: E
authors.lastname: Wada
authors.forename: Makiko
authors.initials: M
authors.lastname: Osawa
authors.forename: Hisaichi
authors.initials: H
authors.lastname: Fujii
authors.forename: Osami
authors.initials: O
authors.lastname: Kubo
authors.forename: Tomokatsu
authors.initials: T
authors.lastname: Hori
mesh_terms: D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002528:Cerebellar Neoplasms / Q000473:pathology / Q000628:therapy*; D002648:Child; D003131:Combined Modality Therapy; D006801:Humans; D008297:Male; D008527:Medulloblastoma / Q000473:pathology / Q000628:therapy*; D036102:Peripheral Blood Stem Cell Transplantation / Q000009:adverse effects; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis; D014182:Transplantation, Autologous
chemical_list: D018719:Erb-b2 Receptor Tyrosine Kinases; C508053:ERBB2 protein, human